CURIS CA-4948-104

{ "short_title": "CURIS CA-4948-104", "data_mode": "900", "data_mode_number": "000002312", "official_title": "A PHASE 1 SINGLE-ARM, OPEN-LABEL STUDY OF CA-4948 IN COMBINATION WITH AZACITIDINE AND VENETOCLAX \r\nIN ACUTE MYELOID LEUKEMIA PATIENTS IN COMPLETE RESPONSE WITH MEASURABLE RESIDUAL DISEASE.", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "gtThird", "ctgov_number": null, "eudract_number": "2023-505828-58", "general_contact_email": "ectu@ukdd.de", "general_contact_phone": "+49 351-4587566", "hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke", "description_laie_de": "Eine einarmige, offene Phase-1-Studie mit CA-4948 in Kombination mit Azacitidin Kombination mit Azacitidin und Venetoclax bei Patienten mit akuter myeloischer Leuk\u00e4mie nach vollst\u00e4ndigem Ansprechen mit messbarem Restmangel Resterkrankung.", "description_laie_en": "A single-arm, open-label, phase 1 study of CA-4948 in combination with azacitidine Combination with azacitidine and venetoclax in patients with acute myeloid leukemia after complete response with measurable residual deficiency Residual disease.", "description_expert_de": "Eine einarmige, offene Phase-1-Studie mit CA-4948 in Kombination mit Azacitidin Kombination mit Azacitidin und Venetoclax bei Patienten mit akuter myeloischer Leuk\u00e4mie nach vollst\u00e4ndigem Ansprechen mit messbarem Restmangel Resterkrankung.", "description_expert_en": "A Phase 1 Single-Arm, Open-Label Study of CA-4948 in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease.", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I", "main_cat_id": 4, "sub_cat_id": 30 }